drugset

drugset / Trial / NCT00184951

Pharmacokinetic Study of Rosuvastatin and Lopinavir/Ritonavir in HIV Patients

NCT00184951 ↗

Phase 2 Completed 30 enrolled Radboud University Medical Center Abbott · collab AstraZeneca · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

open-label, multiple dose, single-group, 12 week trial in HIV-infected patients with hyperlipidemia while using lopinavir/ritonavir; both male or female subjects.

Timeline

Start: 2004-04
Primary completion: 2005-07
Completion: 2005-07

Publications

Results van der Lee M, Sankatsing R, Schippers E, Vogel M, Fatkenheuer G, van der Ven A, Kroon F, Rockstroh J, Wyen C, Baumer A, de Groot E, Koopmans P, Stroes E, Reiss P, Burger D. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Antivir Ther. 2007;12(7):1127-32.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rosuvastatin	Small molecule	10 mg	—
Subject	Rosuvastatin	Small molecule	20 mg	—
Subject	Rosuvastatin	Small molecule	40 mg	—

Indications